AllianceBernstein’s Gyre Therapeutics GYRE Stock Holding History

AllianceBernstein’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$154K	Hold	21,830	–	–	﹤0.01%	3103
2025 Q4	$154K	Hold	21,830	–	–	﹤0.01%	3111
2025 Q3	$163K	Buy	21,830 +1,900	+10%	+$14.4K	﹤0.01%	3125
2025 Q2	$146K	Buy	+19,930	New	+$174K	﹤0.01%	3116
2019 Q2	–	Sell	-1,827	Closed	-$111K	–	3162
2019 Q1	$111K	Sell	1,827 -440	-19%	-$28.3K	﹤0.01%	3001
2018 Q4	$134K	Hold	2,267	–	–	﹤0.01%	2958
2018 Q3	$183K	Hold	2,267	–	–	﹤0.01%	3005
2018 Q2	$198K	Buy	+2,267	New	+$398K	﹤0.01%	2973
2014 Q2	–	Sell	-31	Closed	-$114K	–	3500
2014 Q1	$114K	Sell	31 -5	-14%	-$18.5K	﹤0.01%	2945
2013 Q4	$119K	Sell	36 -8	-18%	-$31.5K	﹤0.01%	2901
2013 Q3	$184K	Sell	44 -3	-6%	-$12.1K	﹤0.01%	2872
2013 Q2	$157K	Buy	+47	New	+$179K	﹤0.01%	2887

Other funds holding GYRE

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AllianceBernstein's GYRE Position: Q1 2026 in Review

AllianceBernstein held its Gyre Therapeutics (GYRE) position steady in Q1 2026 at 21,830 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #3103.

AllianceBernstein first reported a position in GYRE in Q2 2013 and has held it in 12 quarters since. The position peaked at $198K in Q2 2018. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

AllianceBernstein held 21,830 shares of Gyre Therapeutics worth $154K as of Q1 2026.
AllianceBernstein left its Gyre Therapeutics share count unchanged in Q1 2026.
Gyre Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #3103 holding.
AllianceBernstein first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 12 quarters since.
AllianceBernstein's Gyre Therapeutics position peaked at $198K in Q2 2018.
56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.